All In Biotech

NDA 207997 · Novartis

Rydapt

Midostaurin · Oral · Kinase Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: May 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 28, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

53

11 Phase 3, 4 recruiting

FAERS reports

1,957

1,424 serious, 472 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 8, 2026.

RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 ) 1.1 Acute Myeloid Leukemia RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by an FDA approved test [see Dosage and Administration (2.1), Clinical Studies (14.1)]. Limitations of Use RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. 1.2 Systemic Mastocytosis RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

Mechanism: Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFRα/β, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 24, 2020 Supplement 6 · Efficacy · priority review OrphanLabelLetter
  • Apr 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
  • Apr 28, 2017 Original approval · Efficacy · priority review NovelOrphanLabelLetter
1 products under this application
  • RYDAPT · MIDOSTAURIN 25MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Midostaurin" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death329
  • nausea166
  • vomiting105
  • drug ineffective100
  • acute myeloid leukaemia recurrent93
  • pancytopenia93
  • pyrexia91
  • diarrhoea90
  • febrile neutropenia78
  • bone marrow failure76
  • drug intolerance73
  • lymphadenopathy60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2017182
2018299
2019342
2020365
2021280
2022160
2023148
202484
202537
202660

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rydapt (Midostaurin)

2024 spending

$27.4M

Beneficiaries

330

1,389 claims

Per beneficiary

$83,116

$191.35 per unit

View as table
YearSpending
2020$37,074,047
2021$35,250,983
2022$30,083,178
2023$30,688,892
2024$27,428,239

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 59 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.